Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Leukemia

Title: Leukemia

ISSN (Electronic): 1476-5551

ISSN (Print): 0887-6924

Publication date (Electronic): Jul 2015

Volume: 29

Issue: 7

Affiliations

[1 ] German CLL Study Group (GCLLSG), Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany.

[2 ] Oncology Practice, Würzburg, Germany.

[3 ] Department of Hematology, Centre Henri Becquerel, Rouen, France.

[4 ] Department of Hematology, Hospital Virgen de la Salud, Toledo, Spain.

[5 ] Department of Hematology and Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy.

[6 ] Department of Hematology, University Hospital of Wales, Cardiff, UK.

[7 ] F. Hoffmann-La Roche Ltd, Basel, Switzerland.

[8 ] F. Hoffmann-La Roche Ltd, Welwyn, UK.

[9 ] 1] German CLL Study Group (GCLLSG), Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany [2] Cluster of Excellence 'Cellular Stress Responses in Aging Associated Diseases' (CECAD), University of Cologne, Cologne, Germany.

Article

Publisher Item ID: leu201514

DOI: 10.1038/leu.2015.14

PubMed ID: 25634683

SO-VID: 90aa827e-906a-4af1-998b-16aa2b2746fe

History

Data availability:

Comments

Comment on this article

scite_

Cited by 69

See all cited by